Overview
The marketing authorisation for Alpivab has been withdrawn at the request of the marketing-authorisation holder.
Alpivab : EPAR - Medicine overview
English (EN)
(650.2 KB - PDF)View
български (BG)
(1.27 MB - PDF)
español (ES)
(1.2 MB - PDF)
čeština (CS)
(1.26 MB - PDF)
dansk (DA)
(1.2 MB - PDF)
Deutsch (DE)
(1.2 MB - PDF)
eesti keel (ET)
(1.2 MB - PDF)
ελληνικά (EL)
(1.28 MB - PDF)
français (FR)
(1.2 MB - PDF)
hrvatski (HR)
(1.22 MB - PDF)
italiano (IT)
(1.2 MB - PDF)
latviešu valoda (LV)
(1.26 MB - PDF)
lietuvių kalba (LT)
(1.22 MB - PDF)
magyar (HU)
(1.25 MB - PDF)
Malti (MT)
(1.26 MB - PDF)
Nederlands (NL)
(1.2 MB - PDF)
polski (PL)
(1.25 MB - PDF)
português (PT)
(1.2 MB - PDF)
română (RO)
(1.22 MB - PDF)
slovenčina (SK)
(1.26 MB - PDF)
slovenščina (SL)
(1.25 MB - PDF)
Suomi (FI)
(1.2 MB - PDF)
svenska (SV)
(1.2 MB - PDF)
Product information
Alpivab : EPAR - Product Information
English (EN)
(1.57 MB - PDF)View
български (BG)
(3.2 MB - PDF)
español (ES)
(2.3 MB - PDF)
čeština (CS)
(2.77 MB - PDF)
dansk (DA)
(2.25 MB - PDF)
Deutsch (DE)
(2.3 MB - PDF)
eesti keel (ET)
(2.23 MB - PDF)
ελληνικά (EL)
(3.21 MB - PDF)
français (FR)
(2.29 MB - PDF)
hrvatski (HR)
(2.31 MB - PDF)
íslenska (IS)
(2.25 MB - PDF)
italiano (IT)
(2.28 MB - PDF)
latviešu valoda (LV)
(2.89 MB - PDF)
lietuvių kalba (LT)
(2.37 MB - PDF)
magyar (HU)
(2.75 MB - PDF)
Malti (MT)
(2.78 MB - PDF)
Nederlands (NL)
(2.27 MB - PDF)
norsk (NO)
(2.24 MB - PDF)
polski (PL)
(2.84 MB - PDF)
português (PT)
(2.28 MB - PDF)
română (RO)
(2.4 MB - PDF)
slovenčina (SK)
(2.76 MB - PDF)
slovenščina (SL)
(2.71 MB - PDF)
Suomi (FI)
(2.25 MB - PDF)
svenska (SV)
(2.26 MB - PDF)
Latest procedure affecting product information: T/0004
20/11/2020
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Alpivab : EPAR - All Authorised presentations
English (EN)
(581.31 KB - PDF)View
български (BG)
(1.17 MB - PDF)
español (ES)
(1.13 MB - PDF)
čeština (CS)
(1.15 MB - PDF)
dansk (DA)
(1.12 MB - PDF)
Deutsch (DE)
(1.12 MB - PDF)
eesti keel (ET)
(1.12 MB - PDF)
ελληνικά (EL)
(1.17 MB - PDF)
français (FR)
(1.12 MB - PDF)
hrvatski (HR)
(1.14 MB - PDF)
íslenska (IS)
(1.13 MB - PDF)
italiano (IT)
(1.12 MB - PDF)
latviešu valoda (LV)
(1.16 MB - PDF)
lietuvių kalba (LT)
(1.14 MB - PDF)
magyar (HU)
(1.15 MB - PDF)
Malti (MT)
(1.16 MB - PDF)
Nederlands (NL)
(1.13 MB - PDF)
norsk (NO)
(1.12 MB - PDF)
polski (PL)
(1.16 MB - PDF)
português (PT)
(1.13 MB - PDF)
română (RO)
(1.14 MB - PDF)
slovenčina (SK)
(1.16 MB - PDF)
slovenščina (SL)
(1.15 MB - PDF)
Suomi (FI)
(1.12 MB - PDF)
svenska (SV)
(1.13 MB - PDF)
Product details
- Name of medicine
- Alpivab
- Active substance
- Peramivir
- International non-proprietary name (INN) or common name
- peramivir
- Therapeutic area (MeSH)
- Influenza, Human
- Anatomical therapeutic chemical (ATC) code
- J05AH03
Pharmacotherapeutic group
Antivirals for systemic useTherapeutic indication
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Assessment history
Alpivab : EPAR - Procedural steps taken and scientific information after authorisation
English (EN)
(1.2 MB - PDF)View
Topics
This page was last updated on